For the Inventor, By the Inventor

Enter assignee name

Culver City, CA, United States of America

Nantbio, Inc.

USPTO Granted Patents = 52

EPO Patents = 5

Forward Citations = 35

Loading Chart...

Loading Chart...

54 inventors (with patents filed for the assignee):

Kayvan R Niazi (37 out of 90 patents)

Patrick Soon-Shiong (17 out of 443 patents)

Clifford Anders Olson (12 out of 14 patents)

4. Shahrooz Rabizadeh (11 out of 82 patents)

5. Chunlin Tao (8 out of 32 patents)

6. Shiho Tanaka (8 out of 11 patents)

7. Philip T Liu (7 out of 10 patents)

8. Qinwei Wang (7 out of 14 patents)

9. Peter Sieling (6 out of 8 patents)

10. Raymond Wong (6 out of 9 patents)

11. Paul Weingarten (6 out of 10 patents)

12. Stephen Charles Benz (5 out of 53 patents)

13. Heather McFarlane (5 out of 5 patents)

14. Wael Tadros (5 out of 5 patents)

15. Nicholas James Witchey (5 out of 143 patents)

Core Competencies:

Live Cell Imaging

Immune Response Validation

Mesenchymal Stem Cell Exosomes

Chimeric T Cell Receptors

Cellular Adjuvants

mRNA Display Antibody Library

Anti-TIM3 Monoclonal Antibodies

Targeted IL-12 Treatments

Tumor Characterization

Reprogrammed T Cell-like NK Cells

Viral Infection Treatments

Trk Inhibition

52 patents: Sort by Forward Citations

1. 12416635 - Live cell imaging systems and methods to validate triggering of immune response (2025-09-16),

2. 12412639 - Method of characterizing a tumor based on an immune gene expression signature in regulatory T cell (Treg)-enriched tumor samples (2025-09-09),

3. 12397019 - Mesenchymal stem cell derived exosomes and methods (2025-08-26),

4. 12385903 - RP182 compositions and methods (2025-08-12),

5. 12350323 - Cellular adjuvants for viral infection (2025-07-08),

6. 12350316 - IL7-IL 15 TxM compositions and methods (2025-07-08),

7. 12329809 - Cellular adjuvants for viral infection (2025-06-17),

8. 12308095 - Prediction of computational pathway circuits (2025-05-20),

9. 12280092 - Reprogrammed T cell-like NK cells (2025-04-21),

10. 12263189 - Mesenchymal stem cell derived exosomes and methods (2025-04-01),

11. 12252525 - Chimeric T cell receptors, nucleic acids, and methods of making and using the same (2025-03-18),

12. 12247086 - Enhanced immunogenicity for GPI-anchored antigens (2025-03-11),

13. 12220452 - Cellular adjuvants for viral infection (2025-02-11),

14. 12098201 - Anti-TIM3 monoclonal antibodies and chimeric antigen receptors (2024-09-24),

15. 12098177 - Targeted IL-12 treatments and methods to stimulate haNK and NK92mi cells (2024-09-24),

NantBio, Inc. is a biotechnology company focused on developing innovative and targeted therapeutics to address unmet medical needs. With a strong emphasis on cancer research, NantBio aims to revolutionize the treatment and diagnosis of various diseases. Through cutting-edge technology and strategic collaborations, the company is dedicated to improving patient outcomes and transforming the field of biomedicine.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 16 2025

52 Patents

#7 in Culver City, CA

#1,543 in California

#6,539 in US

#13,151 in the World

Culver City, CA, United States of America

Nantbio, Inc.

Forward Citations = 35

54 inventors:

Kayvan R Niazi (37 out of 90 patents)

Patrick Soon-Shiong (17 out of 443 patents)

Clifford Anders Olson (12 out of 14 patents)

4. Shahrooz Rabizadeh (11 out of 82 patents)

5. Chunlin Tao (8 out of 32 patents)

Please report any incorrect information to support@idiyas.com

Loading…